OPS-2071 / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
OPS-2071 / Otsuka
NCT02473393: A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis

Completed
2
43
Japan, RoW
OPS-2071 tablet
Otsuka Pharmaceutical Co., Ltd.
Bacterial Enteritis
03/17
03/17
NCT03850509 / 2019-000176-41: Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

Terminated
2
3
Europe, US
OPS-2071, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., IQVIA Pvt. Ltd
Crohn's Disease
05/20
05/20
NCT05923892: Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Recruiting
2
80
RoW
OPS-2071, OPS-2071 tablets, placebo, placebo tablets
Otsuka Beijing Research Institute
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
08/24
08/24

Download Options